期刊文献+

武汉地区24家医院2006-2008年睡眠障碍治疗药物应用分析 被引量:2

原文传递
导出
摘要 目的:研究睡眠障碍治疗药物在武汉地区的应用情况和发展趋势。方法:采用世界卫生组织推荐的限定日剂量为指标的分析方法,对武汉地区24家医院2006-2008年睡眠障碍治疗药物有关数据进行统计分析。结果:睡眠障碍治疗药物销售金额逐年增加,苯二氮芯卓(BZD)类药物占据使用频度的构成比最高,用于改善睡眠障碍的中药制剂销售金额与使用频度明显增加。结论:BZD类药物仍然是睡眠障碍治疗的一线用药,中药在治疗睡眠障碍领域越来越受到重视。综合考虑安全性、有效性和经济性,是人们选择药物的重要因素。
作者 刘东 张程亮
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2011年第4期334-336,共3页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献8

二级参考文献23

  • 1窦伟,赵忠新.镇静催眠药物的耐受性研究进展[J].中华神经科杂志,2004,37(5):459-462. 被引量:7
  • 2邹豪,邵元福,朱才娟,邓渝林,马玉杰,陈盛新.医院药品DDD数排序分析的原理及利用[J].中国药房,1996,7(5):215-217. 被引量:1426
  • 3江帆,邱畅,李小芳.2003~2005年催眠药物用药分析[J].汕头大学医学院学报,2006,19(2):107-108. 被引量:10
  • 4沈渔邮主编.精神病学[M].第四版.北京:人民卫生出版社,2003:406.
  • 5TAJIMA O. Recent trends in pharmacotherapy for anxiety disorders [ J 1. Nihou Shinkei Seishin Yakurigaku Zasshi, 2004, 24(3) :133 - 136.
  • 6Canadian Psychiatric Association. Clinical Practice Guidelines Management of Anxiety Disorders. 2 Principles of diagnosis and management of anxiety disorder [ J ]. Can J Psychiatry, 2006, 51 ( Suppl 2) : 9 - 22.
  • 7CHARNEY D S. Psychobiological mechanisms of resilience and vulnerability : implications for successful adaptation to extreme stress [ J ]. Am J Psychiatry, 2004, 161 : 195 - 216.
  • 8GORMAN J M. Treating generalized anxiety disorder [ J ]. J Clin Psychiatry, 2003, 64 ( Suppl 2 ) : 24 - 29.
  • 9MENDELSON W B. Combining pharmacologic and nonpharmacologic therapies for insomnia [ J ]. J Clin Psychiatry, 2007, 68(Suppl 5) : 19 -23.
  • 10ERMAN M K. Selected sleep disorders: restless legs syndrome and periodic limb movement disorder, sleep apnea syndrome, and narcolepsy [ J ]. Psychiatr Clin N Am, 2006, 29 (4) : 947 - 967.

共引文献46

同被引文献12

  • 1Weisberg RB. Overview of generalized anxiety disorder:epidemiology, presentation, and course [J]. J Clin Psychiatry, 2009,709(2) :4-9.
  • 2Vicens C, Fiol F, Llobera J,etal. Withdrawal from long-term benzodiazepine use: randomised trial in family practice[J]. Br J Gen Praet, 2006,56 (533) : 958-963.
  • 3中华人民共和国卫生部.精神药品临床应用指导原则[S].卫医发第39号.2007.
  • 4Anthierens S, Habraken H, Petrovic M, et al. The lesser evil? Initiating a benzodiazepine prescription in general practice: a qualitative study on GPs' perspectives [J]. Scand J Prim Health Care, 2007, 25(4):214-219.
  • 5Vicens C, Fiol F, Llobera J,et al. Withdrawal from long-term benzodiazepine use: randomised trial in family practice[J]. Br J Gen Pract, 2006,56 (533) : 958-963.
  • 6Zitman FG, Couvee JE. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group[J]. Br J Psychiatry, 2001, 178:317-324.
  • 7Valenstein M, Taylor KK, Austin K, et al. Benzodiazepine use among depressed patients treated in mental health settings [J].Am J Psychiatry, 2004,161 (4) :654-661.
  • 8Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long- term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial[J]. Br J Psychiatry, 2003, 182:498-504.
  • 9Anthierens S, Habraken H, Petrovic M, et al. First benzodiazepine prescriptions: qualitative study of patients' perspectives [J]. Can Fam Physician, 2007, 53(7) : 1200-1201.
  • 10Valenstein M, Taylor KK, Austin K, et al. Benzodiazepine use among depressed patients treated in mental health settings [J]. Am J Psychiatry, 2004,161 (4) :654-661.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部